Core Viewpoint - Polyrizon Ltd. has initiated preclinical studies for intranasal Naloxone, aiming to enhance opioid overdose treatment through its innovative Trap and Target™ platform [1][3][4] Company Overview - Polyrizon is a development stage biotech company focused on innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [6] - The company is advancing its proprietary Capture and Contain (C&C) hydrogel technology and the Trap and Target (T&T) platform for nasal delivery of active pharmaceutical ingredients [6] Industry Context - The opioid crisis is a global public health emergency, with a significant rise in overdose fatalities driven by synthetic opioids like fentanyl [4] - The global Naloxone market is projected to reach $2.47 billion by 2032, growing at a CAGR of 11%, while the intranasal Naloxone spray market is expected to reach $1.4 billion by 2030 [4] Research and Development - The preclinical studies will evaluate key parameters such as drug loading capacity, release kinetics, nasal deposition, and stability, which are essential for further safety and efficacy testing [3] - The T&T platform is designed to optimize drug delivery, potentially enhancing the bioavailability and effectiveness of intranasal Naloxone [4]
Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform